Oluwatosin Oniyide

TL;DR: In this paper, the authors quantified levels of SARS-CoV-2-reactive antibodies and hCoVreactive antibody in serum samples collected from 431 individuals before the COVID-19 pandemic, and then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS CoV 2.

TL;DR: In this article, three protein arrays were developed to measure IgG autoantibodies associated with connective tissue diseases, anti-cytokine antibodies, and anti-viral antibody responses in serum from 147 hospitalized COVID-19 patients.

TL;DR: These studies indicate that most individuals possessed hCoV-reactive antibodies before the COVID-19 pandemic, and that ~23% of these individuals possessed non-neutralizing antibodies that cross-reacted with SARS- CoV-2 spike and nucleocapsid proteins.

TL;DR: In this article, three different protein arrays were developed to measure hallmark IgG autoantibodies associated with Connective Tissue Diseases (CTDs), Anti-Cytokine Antibodies (ACA), and anti-viral antibody responses in 147 hospitalized COVID-19 patients in three different centers.

TL;DR: In this article, the authors found that patients with hematologic cancers had a significantly higher mortality relative to patients with solid cancers after accounting for confounders including ECOG performance status and active cancer status.